Drug induced phospholipidosis: an acquired lysosomal storage disorder

Biochim Biophys Acta. 2013 Mar;1831(3):602-11. doi: 10.1016/j.bbalip.2012.08.013. Epub 2012 Aug 30.

Abstract

There is a strong association between lysosome enzyme deficiencies and monogenic disorders resulting in lysosomal storage disease. Of the more than 75 characterized lysosomal proteins, two thirds are directly linked to inherited diseases of metabolism. Only one lysosomal storage disease, Niemann-Pick disease, is associated with impaired phospholipid metabolism. However, other phospholipases are found in the lysosome but remain poorly characterized. A recent exception is lysosomal phospholipase A2 (group XV phospholipase A2). Although no inherited disorder of lysosomal phospholipid metabolism has yet been associated with a loss of function of this lipase, this enzyme may be a target for an acquired form of lysosomal storage, drug induced phospholipidosis. This article is part of a Special Issue entitled Phospholipids and Phospholipid Metabolism.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acyltransferases / metabolism*
  • Amino Acid Sequence
  • Animals
  • Humans
  • Kinetics
  • Lipolysis / drug effects*
  • Lysophospholipids / metabolism*
  • Lysosomal Storage Diseases, Nervous System / etiology
  • Lysosomal Storage Diseases, Nervous System / metabolism*
  • Lysosomal Storage Diseases, Nervous System / pathology
  • Lysosomes / drug effects
  • Lysosomes / metabolism
  • Mice
  • Molecular Sequence Data
  • Monoglycerides / metabolism*
  • Niemann-Pick Diseases / metabolism
  • Niemann-Pick Diseases / pathology
  • Phospholipases A2 / metabolism*
  • Proteins / agonists
  • Proteins / metabolism*
  • Xenobiotics / adverse effects*

Substances

  • Lysophospholipids
  • Monoglycerides
  • Proteins
  • Xenobiotics
  • bis(monoacylglyceryl)phosphate
  • lysosomal proteins
  • Acyltransferases
  • Phospholipases A2
  • phospholipase A2, group XV